Antman KH - Search Results

1

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.

Vogelzang NJ, Weissman LB, Herndon JE 2nd, Antman KH, Cooper MR, Corson JM, Green MR. Vogelzang NJ, et al. Among authors: antman kh. J Clin Oncol. 1994 Jul;12(7):1436-42. doi: 10.1200/JCO.1994.12.7.1436. J Clin Oncol. 1994. PMID: 8021735 Clinical Trial.

2

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon JE 2nd, Aisner J, Ellison RR, Leone L, et al. Chahinian AP, et al. J Clin Oncol. 1993 Aug;11(8):1559-65. doi: 10.1200/JCO.1993.11.8.1559. J Clin Oncol. 1993. PMID: 8336195 Clinical Trial.

3

Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.

Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer SJ, Lee TH, Corson JM, Antman KH. Sugarbaker DJ, et al. Among authors: antman kh. J Clin Oncol. 1993 Jun;11(6):1172-8. doi: 10.1200/JCO.1993.11.6.1172. J Clin Oncol. 1993. PMID: 8501504

4

Malignant mesothelioma following treatment for Hodgkin's disease.

Weissmann LB, Corson JM, Neugut AI, Antman KH. Weissmann LB, et al. Among authors: antman kh. J Clin Oncol. 1996 Jul;14(7):2098-100. doi: 10.1200/JCO.1996.14.7.2098. J Clin Oncol. 1996. PMID: 8683242

5

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.

Yogelzang NJ, Herndon JE 2nd, Cirrincione C, Harmon DC, Antman KH, Corson JM, Suzuki Y, Citron ML, Green MR. Yogelzang NJ, et al. Among authors: antman kh. Cancer. 1997 Jun 1;79(11):2237-42. doi: 10.1002/(sici)1097-0142(19970601)79:11<2237::aid-cncr23>3.0.co;2-w. Cancer. 1997. PMID: 9179072 Clinical Trial.

6

Malignant mesothelioma of the tunica vaginalis testis.

Antman K, Cohen S, Dimitrov NV, Green M, Muggia F. Antman K, et al. J Clin Oncol. 1984 May;2(5):447-51. doi: 10.1200/JCO.1984.2.5.447. J Clin Oncol. 1984. PMID: 6726298

7

Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.

Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J. Antman K, et al. J Clin Oncol. 1988 Jan;6(1):147-53. doi: 10.1200/JCO.1988.6.1.147. J Clin Oncol. 1988. PMID: 3335886

8

Benign and malignant pleural mesothelioma.

Antman KH, Corson JM. Antman KH, et al. Clin Chest Med. 1985 Mar;6(1):127-40. Clin Chest Med. 1985. PMID: 3891207 Review.

9

Malignant mesothelioma following radiation exposure.

Antman KH, Corson JM, Li FP, Greenberger J, Sytkowski A, Henson DE, Weinstein L. Antman KH, et al. J Clin Oncol. 1983 Nov;1(11):695-700. doi: 10.1200/JCO.1983.1.11.695. J Clin Oncol. 1983. PMID: 6668488

10

Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups.

Antman K, Suit H, Amato D, Corson J, Wood W, Proppe K, Harmon D, Carey R, Greenberger J, Blum R, et al. Antman K, et al. J Clin Oncol. 1984 Jun;2(6):601-8. doi: 10.1200/JCO.1984.2.6.601. J Clin Oncol. 1984. PMID: 6374055 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

196 results

Search Page

Filters